(Q38085054)

28 August 2017

Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults (English)

1 reference

28 August 2017

1 reference

Claudio Ponticelli

1

1 reference

PubMed ID

23445199

28 August 2017

Giorgio Graziani

series ordinal

2

1 reference

28 August 2017

1 March 2013

1 reference

Expert Review of Clinical Immunology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

3

1 reference

28 August 2017

251-261

1 reference

Focal segmental glomerulosclerosis

28 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Cell biology of the glomerular podocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Podocyte is the major culprit accounting for the progression of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Fidelity and evolution of recurrent FSGS in renal allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Induction of B7-1 in podocytes is associated with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb))

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Proteinuria: an enzymatic disease of the podocyte?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Growth-dependent podocyte failure causes glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Focal glomerulosclerosis: natural history and treatment. A report of 70 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Primary focal segmental glomerulosclerosis: clinical course and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Nephrin deficiency activates NF-kappaB and promotes glomerular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-American population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Treatment of primary focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Gonadal Injury Resulting From Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Mycophenolate mofetil treatment for primary glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Clinical trial of focal segmental glomerulosclerosis in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Sirolimus interacts with pathways essential for podocyte integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Rituximab: mechanism of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Endothelin antagonists in clinical trials: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Induction of T regulatory cells attenuates idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECI.12.109

21 January 2018

Identifiers

DOI

10.1586/ECI.12.109

1 reference

release_pqjnrk6lmfen7azv6rjbr23pva

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pqjnrk6lmfen7azv6rjbr23pva

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

23445199

1 reference

PubMed ID

23445199